Teva Pharmaceutical Industries (NYSE:TEVA)‘s stock had its “hold” rating reissued by stock analysts at Wells Fargo & Company in a report issued on Thursday.

Other equities analysts also recently issued research reports about the company. BTIG Research raised Teva Pharmaceutical Industries from a “neutral” rating to a “buy” rating and set a $24.00 target price on the stock in a research report on Monday, September 11th. Gabelli reissued a “buy” rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, September 13th. ValuEngine raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research report on Monday, October 2nd. Evercore ISI set a $38.00 target price on Teva Pharmaceutical Industries and gave the company a “buy” rating in a research report on Wednesday, October 25th. Finally, TheStreet downgraded Teva Pharmaceutical Industries from a “c-” rating to a “d+” rating in a research report on Friday, August 25th. Seven equities research analysts have rated the stock with a sell rating, eighteen have assigned a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $19.34.

Teva Pharmaceutical Industries (NYSE TEVA) traded down $0.82 during midday trading on Thursday, hitting $15.70. The stock had a trading volume of 30,494,500 shares, compared to its average volume of 15,888,267. The company has a market cap of $16,784.32, a P/E ratio of 3.82 and a beta of 0.55. The company has a current ratio of 0.96, a quick ratio of 0.66 and a debt-to-equity ratio of 1.20. Teva Pharmaceutical Industries has a 52-week low of $10.85 and a 52-week high of $38.31.

Several hedge funds have recently modified their holdings of the business. Security National Bank of Sioux City Iowa IA lifted its holdings in shares of Teva Pharmaceutical Industries by 0.4% in the 2nd quarter. Security National Bank of Sioux City Iowa IA now owns 21,788 shares of the company’s stock worth $724,000 after buying an additional 87 shares during the period. Bronfman E.L. Rothschild L.P. lifted its holdings in shares of Teva Pharmaceutical Industries by 2.6% in the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 3,711 shares of the company’s stock worth $123,000 after buying an additional 94 shares during the period. Sheaff Brock Investment Advisors LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 3.6% in the 2nd quarter. Sheaff Brock Investment Advisors LLC now owns 8,389 shares of the company’s stock worth $279,000 after buying an additional 294 shares during the period. Bank of Nova Scotia lifted its holdings in shares of Teva Pharmaceutical Industries by 8.3% in the 2nd quarter. Bank of Nova Scotia now owns 6,903 shares of the company’s stock worth $229,000 after buying an additional 528 shares during the period. Finally, First National Trust Co. lifted its holdings in shares of Teva Pharmaceutical Industries by 6.7% in the 2nd quarter. First National Trust Co. now owns 8,878 shares of the company’s stock worth $295,000 after buying an additional 555 shares during the period. Institutional investors and hedge funds own 52.05% of the company’s stock.

WARNING: “Teva Pharmaceutical Industries (TEVA) Stock Rating Reaffirmed by Wells Fargo & Company” was posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/12/14/teva-pharmaceutical-industries-teva-stock-rating-reaffirmed-by-wells-fargo-company.html.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.